Malaria is the main cause of death among children under five years old
in the Niger Delta area. Since January 2003, MSF has provided basic health
care in three health centers in Bayelsa State and has introduced artemisinin containing
combination therapy (ACT) using artesunate-amodiaquine as
first-line treatment for malaria patients. A November 2001 study done by
MSF showed resistance levels of approximately 40% for the current first-line
therapy (chloroquine) and 45% for the second-line treatment (Fansidar®) in
children aged 6-59 months. In April 2003, MSF began an HIV/AIDS care and
support project at Lagos General Hospital. MSF also maintains an emergency
preparedness and response project in the capital Abuja.
Table of
Contents
The
Year in Review Rafael Vilasanjuan,
MSF Secretary General Dr. Morten Rostrup, President,
MSF International Council
